OP62 Polymorphisms in AKT1 and EGFR as possible new biomarkers of clinical outcome and toxicity in non-small-cell lung cancer patients treated with gefitinib
Keyword(s):
Keyword(s):
2008 ◽
Vol 135
(6)
◽
pp. 771-782
◽
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
2019 ◽
Vol 3
◽
pp. 25-25